More money is spent advertising alcohol than any other product. For some, it like gambling and cigarettes are pleasant distractions
May 1, 2007 (Press Release) --
. For them their addition is a disease. According to a new report - Anti-addiction Therapies, 2006-2011 - society is crying out for solutions. Which pharmaceutical companies are now aiming to be that cure? This report will tell you.
Doctors and concerned specialists have long maintained a behavioural-based approach to treating addiction is the most effective treatment programme. Suggested pharmaceutical solutions simply did not work. That is it seems...until now. Two leading pharmaceutical companies have developed novel drugs that could revolutionise the treatment of obesity and nicotine addiction. And what is more, those drugs could save health authorities millions of dollars. With the pharmaceutical industry anxiously seeking the next blockbuster product, it is hardly surprising that Chantix and Acomplia are generating so much interest. Are these drugs set to shift the focus of the pharmaceutical industry? Find out today.
Will these drugs really make much of a difference for such complex disorders? Is this not just the industry wary of decline seizing an opportunity to make money? Anti-addiction Therapies, 2006-2011 - assesses the currently available drugs, analysing which pipeline drugs appear to fit unmet needs best. This report also examines which pharmaceutical companies are likely to be market leaders by 2011.
Pfizer's Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis' Acomplia might provide not only much needed effective relief to thousands of addicts, but could also help develop and drive a market as Viagra did for erectile dysfunction. Markets that are currently worth $1 billion could multiply several-fold within the foreseeable future.
"If Chantix and Acomplia prove to be as effective, but with the minimal side effect profiles that Pfizer and Sanofi-Aventis claim, then we could see significant development in these treatment markets," commented visiongain market analyst and author of this latest report, Tristan Heath. This optimism is based upon the increasing incidence of obesity throughout the developed world and the stated wish of 70% of smokers to quit tobacco. Health authorities throughout the developed world have placed these health issues as top priorities. This is a potential market you cannot afford to ignore. Imagine the potential success your company could aachieve through being informed of this market now.
For more information, Please visit : http://www.bharatbook.com/detail.asp?id=40503
or email us at : info@bharatbook.com
You can also call us at +91-(022)-2757 8668 or +91-(022)-2757 9131
Doctors and concerned specialists have long maintained a behavioural-based approach to treating addiction is the most effective treatment programme. Suggested pharmaceutical solutions simply did not work. That is it seems...until now. Two leading pharmaceutical companies have developed novel drugs that could revolutionise the treatment of obesity and nicotine addiction. And what is more, those drugs could save health authorities millions of dollars. With the pharmaceutical industry anxiously seeking the next blockbuster product, it is hardly surprising that Chantix and Acomplia are generating so much interest. Are these drugs set to shift the focus of the pharmaceutical industry? Find out today.
Will these drugs really make much of a difference for such complex disorders? Is this not just the industry wary of decline seizing an opportunity to make money? Anti-addiction Therapies, 2006-2011 - assesses the currently available drugs, analysing which pipeline drugs appear to fit unmet needs best. This report also examines which pharmaceutical companies are likely to be market leaders by 2011.
Pfizer's Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis' Acomplia might provide not only much needed effective relief to thousands of addicts, but could also help develop and drive a market as Viagra did for erectile dysfunction. Markets that are currently worth $1 billion could multiply several-fold within the foreseeable future.
"If Chantix and Acomplia prove to be as effective, but with the minimal side effect profiles that Pfizer and Sanofi-Aventis claim, then we could see significant development in these treatment markets," commented visiongain market analyst and author of this latest report, Tristan Heath. This optimism is based upon the increasing incidence of obesity throughout the developed world and the stated wish of 70% of smokers to quit tobacco. Health authorities throughout the developed world have placed these health issues as top priorities. This is a potential market you cannot afford to ignore. Imagine the potential success your company could aachieve through being informed of this market now.
For more information, Please visit : http://www.bharatbook.com/detail.asp?id=40503
or email us at : info@bharatbook.com
You can also call us at +91-(022)-2757 8668 or +91-(022)-2757 9131
Email
Print
SPAM
